FULC FY 2022 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-66.9% YoY

Gross Profit

-$70M-1110.7% margin

Operating Income

-$113M-1774.9% margin

Net Income

-$110M-1732.4% margin

EPS (Diluted)

$-2.35

Cash Flow

Operating Cash Flow

-$97M

Free Cash Flow

-$99M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$227M

Total Liabilities

$28M

Stockholders' Equity

$199M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$19M	-66.9%
Gross Profit	-$70M	-$51M	-39.4%
Operating Income	-$113M	-$81M	-38.9%
Net Income	-$110M	-$81M	-35.9%